搜尋結果
藥明巨諾宣佈與 2seventy bio達成獨家戰略合作,開發自身免疫疾病CAR-T治療產品
PR Newswire Asia· 5 個月前上海2024年1月2日 /美通社/ -- 藥明巨諾(港交所代碼:2126),一家獨立的、專注於研發、生產及商業化 ...
ESG: The Key To Future Business Success
ACCESSWIRE· 2 年前NORTHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Inogen Alliance In the world of business ...
IOC Emphasises Power of Sport in Combatting Youth Violence and Crime at Special UNODC Forum
ACCESSWIRE· 2 年前NORTHAMPTON, MA / ACCESSWIRE / November 9, 2022 / Sport and Olympism play a key role in ...
藥明巨諾與2seventy bio宣佈達成戰略合作,加速T細胞免疫治療的研發
PR Newswire Asia· 2 年前雙方的首要合作是在中國加速開發用於治療實體腫瘤的2seventy的MAGE-A4項目 中國上海和美國馬薩諸塞州 ...
No-Cost Resources Available From Discovery Education To Support Student Health During and ...
ACCESSWIRE· 2 年前Discovery Education - the worldwide edtech leader whose state-of-the-art digital platform ...